Singapore-based supplement brand elivity has introduced NANOBOOST, a sublingual spray delivery system developed with a biotech spinoff of Hamburg University, that uses liposomes, nanoemulsions and micelles to carry active compounds across mucosal tissue into circulation rather than through the digestive tract. The company positions the technology as a response to the gap between labeled dose and absorbed dose, currently applied to an energy and a melatonin formulation, with mood, stress, female health and skin products planned. The absorption claims are company-stated and not accompanied by published clinical data in the announcement.
Key Points
- Sublingual spray bypasses stomach acid, enzymes and shifting gastric pH
- Liposomes and nanoemulsions shield compounds from oxidation before circulation
- Bioavailability claims are company-reported, without published clinical validation
Longevity Analysis
Dose on a label and dose in circulation are different quantities, and the difference is determined by gastric acidity, enzymatic degradation, first-pass hepatic metabolism and the integrity of the gut lining — all of which vary substantially between individuals and shift with age. Mucosal absorption removes several of those variables, which matters most for compounds known to degrade in transit, though it also removes the digestive tract's role in regulating uptake rate. For anyone building a supplementation protocol, the practical question is not which ingredients appear on the bottle but which reach the tissues that need them, and that question is answered by measurement over time rather than by delivery-format claims.
Original published by Longevity.Technology, by Kyle Umipig.